Abstract
Sarcopenia is defined as the combined loss of skeletal muscle strength, function, and/or mass with aging. This degenerative loss of muscle mass is associated with poor quality of life and early mortality humans. The loss of muscle mass occurs due to acute changes in daily muscle net protein balance (NPB). It is generally believed a poor NPB occurs due to reduced muscle protein synthetic responses to exercise, dietary amino acid availability, or an insensitivity of insulin to suppress breakdown. Hence, aging muscles appear to be resistant to the anabolic action of exercise and protein (amino acids or hormonal) when compared to their younger counterparts. The mechanisms that underpin anabolic resistance to anabolic stimuli (protein and resistance exercise) are multifactorial and may be partly driven by poor lifestyle choices (increased sedentary time and reduced dietary protein intake) as well as an inherent dysregulated mechanism in old muscles irrespective of the environmental stimuli. The insulin like growth factor 1 (IGF-1), Akt /Protein Kinase B and mechanistic target of rapamycin (mTOR) pathway is the primary driver between mechanical contraction and protein synthesis and may be a site of dysregulation between old and younger people. Therefore, our review aims to describe and summarize the differences seen in older muscle in this pathway in response to resistance exercise (RE) and describe approaches that researchers have sought out to maximize the response in muscle. Furthermore, this review will present the hypothesis that inositol hexakisphosphate kinase 1 (IP6K1) may be implicated in IGF-1 signaling and thus sarcopenia, based on recent evidence that IGF-1 and insulin share some intracellular bound signaling events and that IP6K1 has been implicated in skeletal muscle insulin resistance.
Setting the Scene
Sarcopenia is defined as the combined loss of skeletal muscle mass, function and strength () and it can progress at a rate of approximately 0.8% skeletal muscle loss per year from the 5th decade in adult life (). Sarcopenia is diagnosed using a battery of clinical assessments and globally effects 1 in 10 adults above the age of 60 (). Given that sarcopenia costs the American Health
Service an estimated $18.5 billion annually () and the United Kingdom's National Health Service £4592 for 11% of the total aging population which costs £2.5 billion annually (), it is important that we develop a greater understanding of the cellular pathways that drive this disease and how interventions such as exercise and dietary protein are used to delay this processes implicated in its progression.
Human skeletal muscle is of high plasticity and is in a constant state of remodeling. Skeletal muscle remodeling occurs due to the dynamic balance between muscle protein synthesis (MPS) and muscle protein breakdown rates (MPB). The daily difference between MPS and MPB defines net protein balance (NPB), which is a key regulator of overall skeletal muscle mass. A positive NPB is generally indicative of a positive remodeling response that can be hypertrophic [i.e., increase fiber cross sectional area ()] or non-hypertrophic [i.e., increased metabolic quality (, )] in nature, whereas a reduced NPB reflects an overt phenotype being negative by inducing a loss of muscle mass or poor metabolic
quality (). Changes in MPB are small in normal aging, whilst changes in MPS seem to be larger in amplitude and more obvious in response to the main anabolic stimuli to muscle tissue. As such, the measurement of MPS is the primary focus in human metabolic research ().
Protein ingestion stimulates an increase in MPS; however, a decrease in habitual physical activity, which is often observed with aging and/or injury, can induce anabolic resistance of MPS to protein ingestion () (Figure 1). For example, 7 days of unilateral leg immobilization in young men caused significant decreases in quadriceps cross sectional area (CSA) compared to the control limb and leucine supplementation did not reduce the loss in CSA (). Similarly, 14 days immobilization in young men caused decreased CSA and an amino acid infusion in varying doses showed decreased post prandial MPS in the immobilized leg vs. the control limb (). To reach the same myofibrillar protein synthetic response in muscle, older individuals need to consume more relative amounts of protein than younger individuals. In vivo, the stimulation of myofibrillar protein synthesis rates is dependent on intracellular molecular signaling pathways that become activated in response to extracellular cues. The mTOR complex 1 (mTORC1) pathway appears to play an important role in stimulating postprandial / post-exercise myofibrillar protein synthesis rates (), and activation of this pathway can occur in two ways; firstly, through mechanical contraction (i.e., resistance exercise) which causes a release of skeletal muscle IGF-1 () and secondly via amino acid/protein intake (). Furthermore, resistance exercise (RE) plus protein ingestion increases mTORC1 phosphorylation to a greater extent than protein or RE alone (, ), and likely intracellular redistribution of mTORC1 toward the sarcolemma as well ().
Figure 1
As humans age, the muscle's ability to respond to both exercise and dietary protein diminishes leading to reduced NPB, and particularly in the myofibrillar protein fraction (
Inositol hexakisphosphate kinase 1 (IP6K1) has recently been shown to inhibit Akt308 activity in IGF-1 stimulated hepatic cell lines (
Molecular Regulation of Muscle Protein Synthesis (MPS) in Response to Exercise and Nutrition
MPS is regulated by an intrinsic cell signaling response which is activated by various external cues, such as dietary amino acids and RE. These cues drive the molecular regulation that augments MPS rates which facilitates the protein remodeling response in skeletal muscle, which is generally considered to be a hypertrophic response when studied during recovery from RE. The muscle protein remodeling response after endurance exercise is likely more aimed at non-hypertrophic remodeling. What is noteworthy is that it is still unclear how different anabolic signaling pathways coordinate the synthesis of specific muscle protein sub-fractions such as myofibrillar or mitochondrial proteins throughout the postprandial or post-exercise period. In addition, the time course of activation for these signaling transduction pathways is still unclear. The signaling response to RE and protein is described in detail below both in healthy and anabolic resistant phenotypes.
Insulin Like Growth Factor-1 Activation
IGF-1, owing its name to high homogeneity to insulin, is a small peptide structurally bound by 70 amino acids (
IGF-1 enters the cell via IGFR, it triggers phosphoinositide 3-kinase (P13-K) to generate hosphatidylinositol (
Akt-mTOR Signaling in Response to Protein and Resistance Exercise
Akt is a threonine and serine protein kinase which has three isoforms; Akt1, Akt2, and Akt3 (
Downstream, Akt308 activates mTOR complex 1 (mTORC1) at mTOR2448 via the tuberous sclerosis complex (TSC). The TSC is phosphorylated by Akt which then disassociates the TSC from the small GTPase Ras homolog enriched in brain (Rheb) to localize to the lysosome where Rheb and mTORC1 can interact and phosphorylate mTORC1 (
Downstream of mTORC1, two key proteins are activated to regulate muscle mass. Previous efforts have shown that mTORC1 signaling to p70s6k and 4E-BP1 are both required for an optimal amount and quality of muscle mass during hypertrophic remodeling (
Causes of Anabolic Resistance
There are several factors likely contributing toward the anabolic resistance of aging muscles to RE or protein ingestion (
Recently a NAD+ dependent deacetylase called Sirtuin 1 (SIRT1) has gained some attention due to its emerging role in increased cell longevity (
Habitual diet must be considered as a potential attenuating factor of sarcopenia given the reduced response older adults have to protein ingestion and the profound effect this has on skeletal muscle remodeling. Mediterranean diets rich in protein, fats and vegetables have been shown to reduce the risk of sarcopenia through its anti-inflammatory effects and high anti-oxidant content (
Counteracting Anabolic Resistance With Nutrition and Exercise
With the aim of counteracting anabolic resistance, studies have investigated how MPS can be maximized in older adults. Moore et al. (
Figure 2

Normal fluctuations in Muscle Protein Synthesis and Muscle Protein Breakdown rates throughout the day in response to eating a protein containing meal and the effect this has on net protein balance. Protein Requirements to stimulate myofibrillar protein synthesis rates in young and aging populations are described in g/kg of lean body mass These protein meal requirements should be spread equally throughout the day (i.e., 4–5 meal times) to facilitate non-hypertrophic protein remodeling and counterbalance fasting-state protein losses that occurred in between meals (
In summary, RE and higher protein diets have the ability to restore the anabolic sensitivity of MPS rates in aging adults, and either low or high load RE has the ability to stimulate a robust post-exercise muscle protein synthetic response throughout adult life. A sedentary lifestyle and reduced protein intake progressively cause a reduced response to anabolic stimuli (driven by blunted Akt-mTOR signaling), which leads to the progressive loss of muscle mass and function over time. Adults should engage with RE throughout their lives (2–3 times per week), and current evidence suggests that higher dietary protein intakes (0.6 g/kg LBM in each meal X 4–5 meal times) combined with modest caloric restriction is required to support a robust simulation in postprandial MPS rates and perhaps to maintain muscle mass and function with age. It is important to note, however, that a large-scale randomized clinical trial that combines exercise and protein intake manipulations (from RDA and beyond) is needed to confirm the value of eating protein in far excess of the RDA to support a more youthful phenotype with age. In addition, design of RE programme should consider adherence, motivation and enjoyment as these are the key factors for long term participation and ultimately skeletal muscle health.
Possible Mechanism of Anabolic Resistance Involving Inositol Hexakisphosphate Kinase 1 (IP6K1)
Inositol hexakisphosphate kinase 1 (IP6K1) is a six carbon cylitol kinase which has recently been well documented in the attenuation of insulin resistance and type 2 diabetes (
Figure 3

Schematic diagram illustrating the potential negative role of IP6K1 on Akt translocation to the cell membrane preventing phosphorylation of Akt308 which may reduce mTORC1. IP6K1 enters the nucleus via PA and it then synthesizes IP7 from IP6 which prevents Akt from translocating to the cell membrane and ultimately preventing Akt308 phosphorylation. IGFBP, Insulin like growth factor binding proteins; IGF-1, Insulin like growth factor-1; IP6K1, inositol hexakisphosphate kinase 1; IGFR, Insulin like growth factor receptor; IRS-1, Insulin receptor substrate 1; P13K, phosphoinositide 3-kinase; PIP2, hosphatidylinositol (
Illustrates contraction of skeletal muscle;
Illustrates binding/translocationto the cell membrane;
Illustrates activation;
Illustrates phosphorylation;
Illustrates binding to PH domain and downregulating Akt;
Illustrates preventing translocation to cell membrane.
Recently, our research group showed that IP6K1 was altered in adult (47 years ± 3) skeletal muscle in response to exercise (
To conclude, dysregulated Akt-mTOR signaling in response to RE and protein intake ingesting a current recommended intake (15 g per meal or 0.8 g protein/kg/day) is the primary driver of anabolic resistance and sarcopenia (
Statements
Author contributions
RB was responsible for writing the manuscript. NB, NT, CT, and RM were all responsible for reviewing and contributing to the manuscript. RM was the senior author in the group.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- IP6K1
Inositol hexakisphosphate kinase 1
- IGF-1
Insulin like growth factor-1
- Akt
Protein kinase B
- mTOR
Mechanistic target of rapamycin
- mTORC1
Mechanistic target of rapamycin complex 1
- SIRT1
Sirtuin 1
- AMPK
5′ AMP-activated protein kinase
- Peroxisome proliferator-activated receptor-γ coactivator
PGC-1α
- Nuclear factor kappa-light-chain-enhancer of activated B cells
NF-kB
- PB
Net protein balance
- RE
Resistance exercise
- MPS
Muscle protein synthesis
- MPB
Muscle protein balance
- CSA
Cross sectional area
- IGFR
Insulin like growth factor receptor
- ECM
Extracellular matrix
- IGFBP, Insulin like growth factor binding proteinsl PH
Pleckstrin homology
- P13K
Phosphoinositide 3-kinase
- PA
Phosphotadic acid
- PDK1
Phosphoinositide-dependent kinase-1
- PIP3, Phosphatidylinositol
3,4,5-trisphosphate
- PIP2
Phosphatidylinositol (4,5)-bisphosphate
- mTORC2
Mechanistic target of rapamycin complex 2
- IRS1
Insulin receptor substrate 1
- GLUT-1
Glucose transporter-1
- GLUT-4
Glucose transporter-4
- TSC
Tuberous sclerosis complex
- p70s6k
Ribosomal protein S6 kinase beta-1
- 4E-BP1
4E Binding protein 1
- FSR
Fractional synthesis rate
- IRM
1 Repetition maximum
- IP6
Inositol hexophosphate
- IP7
Inositol pyrophosphate
- TNP, N2-(m-Trifluorobenzyl)
N6-(p-nitrobenzyl)purine
- HIIT
High intensity interval training.
Abbreviations
References
1.
SantilliVBernettiAMangoneMPaoloniM. Clinical definition of sarcopenia. Clin Cases Min Bone Metabol. (2014) 11:177. 10.11138/ccmbm/2014.11.3.177
2.
JanssenI. Evolution of sarcopenia research. Appl Physiol Nutr Metabol. (2010) 35:707–12. 10.1139/H10-067
3.
ShafieeGKeshtkarASoltaniAAhadiZLarijaniBHeshmatR. Prevalence of sarcopenia in the world: a systematic review and meta-analysis of general population studies. J Diabetes Metab Disord. (2017) 16:21. 10.1186/s40200-017-0302-x
4.
JanssenIShepardDSKatzmarzykPTRoubenoffR. The healthcare costs of sarcopenia in the united states. J Am Geriatr Soc. (2004) 52:80–5. 10.1111/j.1532-5415.2004.52014.x
5.
Pinedo-VillanuevaRWestburyLDSyddallHESanchez-SantosMTDennisonEMRobinsonSMet al. Health care costs associated with muscle weakness: a UK population-based estimate. Calcif Tissue Int. (2019) 104:137–44. 10.1007/s00223-018-0478-1
6.
PhillipsSMHartmanJWWilkinsonSB. Dietary protein to support anabolism with resistance exercise in young men. J Am Coll Nutr. (2005) 24:134–9. 10.1080/07315724.2005.10719454
7.
TiptonKDWolfeRR. Exercise, protein metabolism, and muscle growth. Int J Sport Nutr Exerc Metab. (2001) 11:109–32. 10.1123/ijsnem.11.1.109
8.
FryCSDrummondMJGlynnELDickinsonJMGundermannDMTimmermanKLet al. Aging impairs contraction-induced human skeletal muscle mTORC1 signaling and protein synthesis. Skelet Muscle. (2011) 1:11. 10.1186/2044-5040-1-11
9.
FiataroneMAMarksECRyanNDMeredithCNLipsitzLAEvansWJ. High-intensity strength training in nonagenarians: Effects on skeletal muscle. JAMA. (1990) 263:3029–34. 10.1001/jama.1990.03440220053029
10.
BioloGCiocchiBLebenstedtMBarazzoniRZanettiMPlatenPet al. Short-term bed rest impairs amino acid-induced protein anabolism in humans. J Physiol. (2004) 558:381–8. 10.1113/jphysiol.2004.066365
11.
WallBTGorissenSHPenningsBKoopmanRGroenBBVerdijkLBet al. Aging is accompanied by a blunted muscle protein synthetic response to protein ingestion. PLoS ONE. (2015) 10:e0140903. 10.1371/journal.pone.0140903
12.
BreenLPhillipsSM. Skeletal muscle protein metabolism in the elderly: Interventions to counteract the'anabolic resistance'of ageing. Nutr Metab. (2011) 8:68. 10.1186/1743-7075-8-68
13.
BackxEMHorstmanAMMarzuca-NassrGNvan KranenburgJSmeetsJSFuchsCJet al. Leucine supplementation does not attenuate skeletal muscle loss during leg immobilization in healthy, young men. Nutrients. (2018) 10:635. 10.3390/nu10050635
14.
GloverEIPhillipsSMOatesBRTangJETarnopolskyMASelbyAet al. Immobilization induces anabolic resistance in human myofibrillar protein synthesis with low and high dose amino acid infusion. J Physiol. (2008) 586:6049–61. 10.1113/jphysiol.2008.160333
15.
Abou SawanSVlietSParelJTBealsJWMazzullaMWestDWet al. Translocation and protein complex co-localization of mTOR is associated with postprandial myofibrillar protein synthesis at rest and after endurance exercise. Physiol Rep. (2018) 6:e1362810.14814/phy2.13628
16.
ManifavaMSmithMRotondoSWalkerSNiewczasIZoncuRet al. Dynamics of mTORC1 activation in response to amino acids. Elife. (2016) 5:e19960. 10.7554/eLife.19960
17.
DeldicqueLTheisenDFrancauxM. Regulation of mTOR by amino acids and resistance exercise in skeletal muscle. Eur J Appl Physiol. (2005) 94:1–10. 10.1007/s00421-004-1255-6
18.
BurdNAWestDWMooreDRAthertonPJStaplesAWPriorTet al. Enhanced amino acid sensitivity of myofibrillar protein synthesis persists for up to 24 h after resistance exercise in young Men−3. J Nutr. (2011) 141:568–73. 10.3945/jn.110.135038
19.
SongZMooreDRHodsonNWardCDentJRO'learyMFet al. Resistance exercise initiates mechanistic target of rapamycin (mTOR) translocation and protein complex co-localisation in human skeletal muscle. Sci Rep. (2017) 7:5028. 10.1038/s41598-017-05483-x
20.
CuthbertsonDSmithKBabrajJLeeseGWaddellTAthertonPet al. Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle. FASEB J. (2005) 19:422–4. 10.1096/fj.04-2640fje
21.
KumarVSelbyARankinDPatelRAthertonPHildebrandtWet al. Age-related differences in the dose–response relationship of muscle protein synthesis to resistance exercise in young and old men. J Physiol. (2009) 587:211–7. 10.1113/jphysiol.2008.164483
22.
WenYAlimovAPMcCarthyJJ. Ribosome biogenesis is necessary for skeletal muscle hypertrophy. Exerc Sport Sci Rev. (2016) 44:110. 10.1249/JES.0000000000000082
23.
LatresEAminiARAminiAAGriffithsJMartinFJWeiYet al. Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/akt/mammalian target of rapamycin (PI3K/akt/mTOR) pathway. J Biol Chem. (2005) 280:2737–44. 10.1074/jbc.M407517200
24.
HongZPedersenNMWangLTorgersenMLStenmarkHRaiborgC. PtdIns3P controls mTORC1 signaling through lysosomal positioning. J Cell Biol. (2017) 216:4217. 10.1083/jcb.201611073
25.
ChakrabortyAKoldobskiyMABelloNTMaxwellMPotterJJJuluriKRet al. Inositol pyrophosphates inhibit akt signaling, thereby regulating insulin sensitivity and weight gain. Cell. (2010) 143:897–910. 10.1016/j.cell.2010.11.032
26.
NaufahuJElliottBMarkivADunning-ForemanPMcGradyMHowardDet al. High intensity exercise decreases IP6K1 muscle content and improves insulin sensitivity (SI2*) in glucose intolerant individuals. J Clin Endocrinol Metab. (2018) 103:1479–90. 10.1210/jc.2017-02019
27.
StittTNDrujanDClarkeBAPanaroFTimofeyvaYKlineWOet al. The IGF-1/PI3K/akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell. (2004) 14:395–403. 10.1016/S1097-2765(04)00211-4
28.
RinderknechtEHumbelRE. Primary structure of human insulin-like growth factor II. FEBS Lett. (1978) 89:283–6. 10.1016/0014-5793(78)80237-3
29.
TurnerJDRotweinPNovakofskiJBechtelPJ. Induction of mRNA for IGF-I and-II during growth hormone-stimulated muscle hypertrophy. Am J Physiol Endocrinol Metabol. (1988) 255:E517. 10.1152/ajpendo.1988.255.4.E513
30.
BartonERParkSJamesJKMakarewichCAPhilippouAElettoDet al. Deletion of muscle GRP94 impairs both muscle and body growth by inhibiting local IGF production. FASEB J. (2012) 26:3691–702. 10.1096/fj.11-203026
31.
SjögrenKLiuJBladKSkrticSVidalOWalleniusVet al. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA. (1999) 96:7088–92. 10.1073/pnas.96.12.7088
32.
YakarSLiuJStannardBButlerAAcciliDSauerBet al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA. (1999) 96:7324–9. 10.1073/pnas.96.13.7324
33.
CohickWSClemmonsDR. The insulin-like growth factors. Annu. Rev. Physiol. (1993) 55:131–53. 10.1146/annurev.ph.55.030193.001023
34.
HuffmanDMFarias QuipildorGMaoKZhangXWanJApontesPet al. Central insulin-like growth factor-1 (IGF-1) restores whole-body insulin action in a model of age-related insulin resistance and IGF-1 decline. Aging Cell. (2016) 15:181–6. 10.1111/acel.12415
35.
MortonRWOikawaSYWavellCGMazaraNMcGloryCQuadrilateroJet al. Neither load nor systemic hormones determine resistance training-mediated hypertrophy or strength gains in resistance-trained young men. J Appl Physiol. (2016) 121:129–38. 10.1152/japplphysiol.00154.2016
36.
WestDWBurdNAChurchward-VenneTACameraDMMitchellCJBakerSKet al. Sex-based comparisons of myofibrillar protein synthesis after resistance exercise in the fed state. J Appl Physiol. (2012) 112:1805–13. 10.1152/japplphysiol.00170.2012
37.
MortonRWSatoKGallaugherMPOikawaSYMcNicholasPDFujitaSet al. Muscle androgen receptor content but not systemic hormones is associated with resistance training-induced skeletal muscle hypertrophy in healthy, young men. Front Physiol. (2018) 9:1373. 10.3389/fphys.2018.01373
38.
MorimotoLMNewcombPAWhiteEBiglerJPotterJD. Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: genetic factors. Cancer Epidemiol Prevent Biomark. (2005) 14:1394–401. 10.1158/1055-9965.EPI-04-0694
39.
JonesJIGockermanABusbyWHCamacho-HubnerCClemmonsDR. Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I. J Cell Biol. (1993) 121:679–87. 10.1083/jcb.121.3.679
40.
HedeMSSalimovaEPiszczekAPerlasEWinnNNastasiTet al. E-peptides control bioavailability of IGF-1. PLoS ONE. (2012) 7:e51152. 10.1371/journal.pone.0051152
41.
PhilippouABartonER. Optimizing IGF-I for skeletal muscle therapeutics. Growth Hormone IGF Res. (2014) 24:157–63. 10.1016/j.ghir.2014.06.003
42.
O'NeillBTLauritzenHPHirshmanMFSmythGGoodyearLJKahnCR. Differential role of insulin/IGF-1 receptor signaling in muscle growth and glucose homeostasis. Cell Rep. (2015) 11:1220–35. 10.1016/j.celrep.2015.04.037
43.
SchiaffinoSMammucariC. Regulation of skeletal muscle growth by the IGF1-akt/PKB pathway: Insights from genetic models. Skelet Muscle. (2011) 1:4. 10.1186/2044-5040-1-4
44.
ManningBD. Insulin signaling: Inositol phosphates get into the akt. Cell. (2010) 143:861–3. 10.1016/j.cell.2010.11.040
45.
FaissnerAHeckNDobbertinAGarwoodJ. DSD-1-proteoglycan/phosphacan and receptor protein tyrosine phosphatase-beta isoforms during development and regeneration of neural tissues. In: Bähr M, editor. Brain Repair. Boston, MA: Springer (2006). p. 25–53. 10.1007/0-387-30128-3_3
46.
LaiKMGonzalezMPoueymirouWTKlineWONaEZlotchenkoEet al. Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy. Mol Cell Biol. (2004) 24:9295–304. 10.1128/MCB.24.21.9295-9304.2004
47.
GarofaloRSOrenaSJRafidiKTorchiaAJStockJLHildebrandtALet al. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J Clin Invest. (2003) 112:197–208. 10.1172/JCI16885
48.
EastonRMChoHRooversKShinemanDWMizrahiMFormanMSet al. Role for Akt3/protein kinase bγ in attainment of normal brain size. Mol Cell Biol. (2005) 25:1869–78. 10.1128/MCB.25.5.1869-1878.2005
49.
DiezHGarridoJJWandosellF. Specific roles of akt iso forms in apoptosis and axon growth regulation in neurons. PLoS ONE. (2012) 7:e32715. 10.1371/journal.pone.0032715
50.
LiuPGanWChinYROguraKGuoJZhangJet al. PtdIns (3:4, 5) P3-dependent activation of the mTORC2 kinase complex. Cancer Discov. (2015) 5:1194–209. 10.1158/2159-8290.CD-15-0460
51.
ManningBDCantleyLC. AKT/PKB signaling: navigating downstream. Cell. (2007) 129:1261–74. 10.1016/j.cell.2007.06.009
52.
CameraDMEdgeJShortMJHawleyJACoffeyVG. Early time course of akt phosphorylation after endurance and resistance exercise. Med Sci Sports Exerc. (2010) 42:1843–52. 10.1249/MSS.0b013e3181d964e4
53.
DrummondMJDreyerHCPenningsBFryCSDhananiSDillonELet al. Skeletal muscle protein anabolic response to resistance exercise and essential amino acids is delayed with aging. J Appl Physiol. (2008) 104:1452–61. 10.1152/japplphysiol.00021.2008
54.
MenonSDibbleCCTalbottGHoxhajGValvezanAJTakahashiHet al. Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. Cell. (2014) 156:771–85. 10.1016/j.cell.2013.11.049
55.
OgasawaraRFujitaSHornbergerTAKitaokaYMakanaeYNakazatoKet al. The role of mTOR signalling in the regulation of skeletal muscle mass in a rodent model of resistance exercise. Sci. Rep. (2016) 6:31142. 10.1038/srep31142
56.
BolsterDRKubicaNCrozierSJWilliamsonDLFarrellPAKimballSRet al. Immediate response of mammalian target of rapamycin (mTOR)-mediated signalling following acute resistance exercise in rat skeletal muscle. J Physiol. (2003) 553:213–20. 10.1113/jphysiol.2003.047019
57.
CoppJManningGHunterT. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): Phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res. (2009) 69:1821–7. 10.1158/0008-5472.CAN-08-3014
58.
MammucariCMilanGRomanelloVMasieroERudolfRDel PiccoloPet al. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab. (2007) 6:458–71. 10.1016/j.cmet.2007.11.001
59.
FrancauxMDemeulderBNaslainDFortinRLutzOCatyGet al. Aging reduces the activation of the mTORC1 pathway after resistance exercise and protein intake in human skeletal muscle: potential role of REDD1 and impaired anabolic sensitivity. Nutrients. (2016) 8:47. 10.3390/nu8010047
60.
KumarVAthertonPJSelbyARankinDWilliamsJSmithKet al. Muscle protein synthetic responses to exercise: effects of age, volume, and intensity. J Gerontol Ser A: Biomed Sci Med Sci. (2012) 67:1170–7. 10.1093/gerona/gls141
61.
MarabitaMBaraldoMSolagnaFCeelenJJMSartoriRNolteHet al. S6K1 is required for increasing skeletal muscle force during hypertrophy. Cell Rep. (2016) 17:501–13. 10.1016/j.celrep.2016.09.020
62.
BaarKEsserK. Phosphorylation of p70S6kcorrelates with increased skeletal muscle mass following resistance exercise. Am J Physiol Cell Physiol. (1999) 276:C127. 10.1152/ajpcell.1999.276.1.C120
63.
MitchellCJChurchward-VenneTAWestDWBurdNABreenLBakerSKet al. Resistance exercise load does not determine training-mediated hypertrophic gains in young men. J Appl Physiol. (2012) 113:71–7. 10.1152/japplphysiol.00307.2012
64.
DavidsenPKGallagherIJHartmanJWTarnopolskyMADelaFHelgeJWet al. High responders to resistance exercise training demonstrate differential regulation of skeletal muscle microRNA expression. J Appl Physiol. (2010) 110:309–17. 10.1152/japplphysiol.00901.2010
65.
RobertsMDHaunCTMobleyCBMumfordPWRomeroMARobersonPAet al. Physiological differences between low versus high skeletal muscle hypertrophic responders to resistance exercise training: current perspectives and future research directions. Front Physiol. (2018) 9:834. 10.3389/fphys.2018.00834
66.
BurdNAGorissenSHvan LoonLJ. Anabolic resistance of muscle protein synthesis with aging. Exerc Sport Sci Rev. (2013) 41:169–73. 10.1097/JES.0b013e318292f3d5
67.
MarkofskiMMDickinsonJMDrummondMJFryCSFujitaSGundermannDMet al. Effect of age on basal muscle protein synthesis and mTORC1 signaling in a large cohort of young and older men and women. Exp Gerontol. (2015) 65:1–7. 10.1016/j.exger.2015.02.015
68.
CastetsPLinSRionNDi FulvioSRomaninoKGuridiMet al. Sustained activation of mTORC1 in skeletal muscle inhibits constitutive and starvation-induced autophagy and causes a severe, late-onset myopathy. Cell Metab. (2013) 17:731–44. 10.1016/j.cmet.2013.03.015
69.
WilliamsASKangLWassermanDH. The extracellular matrix and insulin resistance. Trends Endocrinol Metabol. (2015) 26:357–66. 10.1016/j.tem.2015.05.006
70.
BealsJWSukiennikRANallabelliJEmmonsRSVan VlietSYoungJRet al. Anabolic sensitivity of postprandial muscle protein synthesis to the ingestion of a protein-dense food is reduced in overweight and obese young adults, 2. Am. J Clin Nutr. (2016) 104:1014–22. 10.3945/ajcn.116.130385
71.
SharplesAPHughesDCDeaneCSSainiASelmanCStewartCE. Longevity and skeletal muscle mass: the role of IGF signalling, the sirtuins, dietary restriction and protein intake. Aging Cell. (2015) 14:511–23. 10.1111/acel.12342
72.
LinRYanDZhangYLiaoXGongGHuJet al. Common variants in SIRT1 and human longevity in a Chinese population. BMC Med Genet. (2016) 17:31. 10.1186/s12881-016-0293-3
73.
GroundsMDRadleyHGGebskiBLBogoyevitchMAShavlakadzeT. Implications of cross-talk between tumour necrosis factor and insulin-like growth factor-1 signalling in skeletal muscle. Clin Exp Pharmacol Physiol. (2008) 35:846–51. 10.1111/j.1440-1681.2007.04868.x
74.
KilicUGokOErenberkUDundarozMRTorunEKucukardaliYet al. A remarkable age-related increase in SIRT1 protein expression against oxidative stress in elderly: SIRT1 gene variants and longevity in human. PLoS ONE. (2015) 10:e0117954. 10.1371/journal.pone.0117954
75.
JingXMWangQQHaoYL. Alterations of Sirt1 and mTOR activity in gastrocnemius muscle of mice with sarcopenia. Basic Clin Med. (2018) 38:922–7. 10.3969/j.issn.1001-6325.2018.07.005
76.
McClureRVillaniA. Mediterranean diet attenuates risk of frailty and sarcopenia: new insights and future directions. JCSM Clin Rep. (2017) 2:1–17. 10.17987/jcsm-cr.v2i2.45
77.
CroweFLKeyTJAllenNEApplebyPNRoddamAOvervadKet al. The association between diet and serum concentrations of IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Prevent Biomark. (2009) 18:1333–40. 10.1158/1055-9965.EPI-08-0781
78.
LarssonSCWolkKBrismarKWolkA. Association of diet with serum insulin-like growth factor I in middle-aged and elderly men. Am J Clin Nutr. (2005) 81:1163–7. 10.1093/ajcn/81.5.1163
79.
WrightCZhouJSayerRKimJCampbellW. Effects of a high-protein diet including whole eggs on muscle composition and indices of cardiometabolic health and systemic inflammation in older adults with overweight or obesity: a randomized controlled trial. Nutrients. (2018) 10:946. 10.3390/nu10070946
80.
AscenziFBarberiLDobrowolnyGVilla Nova BacurauANicolettiCRizzutoEet al. Effects of IGF-1 isoforms on muscle growth and sarcopenia. Aging Cell. (2019) 18:e12954. 10.1111/acel.12954
81.
MooreDRChurchward-VenneTAWitardOBreenLBurdNATiptonKDet al. Protein ingestion to stimulate myofibrillar protein synthesis requires greater relative protein intakes in healthy older versus younger men. J Gerontol Ser A Biol Sci Med Sci. (2015) 70:57–62. 10.1093/gerona/glu103
82.
YangYBreenLBurdNAHectorAJChurchward-VenneTAJosseARet al. Resistance exercise enhances myofibrillar protein synthesis with graded intakes of whey protein in older men. Br J Nutr. (2012) 108:1780–8. 10.1017/S0007114511007422
83.
VolpiECampbellWWDwyerJTJohnsonMAJensenGLMorleyJEet al. Is the optimal level of protein intake for older adults greater than the recommended dietary allowance?J Gerontol Ser A Biomed Sci Med Sci. (2012) 68:677–81. 10.1093/gerona/gls229
84.
JadavRSKumarDBuwaNGanguliSThampattySRBalasubramanianNet al. Deletion of inositol hexakisphosphate kinase 1 (IP6K1) reduces cell migration and invasion, conferring protection from aerodigestive tract carcinoma in mice. Cell. Signal. (2016) 28:1124–36. 10.1016/j.cellsig.2016.04.011
85.
GhoshalSZhuQAsteianALinHXuHErnstGet al. TNP [N2-(m-trifluorobenzyl), N6-(p-nitrobenzyl) purine] ameliorates diet induced obesity and insulin resistance via inhibition of the IP6K1 pathway. Mol Metabol. (2016) 5:903–17. 10.1016/j.molmet.2016.08.008
86.
MackenzieRWElliottBT. Akt/PKB activation and insulin signaling: a novel insulin signaling pathway in the treatment of type 2 diabetes. Diab Metab Syndrome Obesity Targ Therapy. (2014) 7:55. 10.2147/DMSO.S48260
87.
ZhuQGhoshalSRodriguesAGaoSAsterianAKameneckaTMet al. Adipocyte-specific deletion of Ip6k1 reduces diet-induced obesity by enhancing AMPK-mediated thermogenesis. J Clin Invest. (2016) 126:4273–88. 10.1172/JCI85510
88.
GhoshalSTyagiRZhuQChakrabortyA. Inositol hexakisphosphate kinase-1 interacts with perilipin1 to modulate lipolysis. Int J Biochem Cell Biol. (2016) 78:149–55. 10.1016/j.biocel.2016.06.018
89.
MooreDR. Keeping older muscle “young” through dietary protein and physical activity. Adv Nutr. (2014) 5:599S−607S. 10.3945/an.113.005405
90.
PhillipsSMMcGloryC. CrossTalk proposal: the dominant mechanism causing disuse muscle atrophy is decreased protein synthesis. J Physiol. (2014) 592:5341–3. 10.1113/jphysiol.2014.273615
Summary
Keywords
IP6K1, sarcopenia, aging, protein, resistance exercise, anabolic resistance, Akt, mTOR
Citation
Barclay RD, Burd NA, Tyler C, Tillin NA and Mackenzie RW (2019) The Role of the IGF-1 Signaling Cascade in Muscle Protein Synthesis and Anabolic Resistance in Aging Skeletal Muscle. Front. Nutr. 6:146. doi: 10.3389/fnut.2019.00146
Received
29 March 2019
Accepted
23 August 2019
Published
10 September 2019
Volume
6 - 2019
Edited by
Maurizio Muscaritoli, Sapienza University of Rome, Italy
Reviewed by
Miguel Luiz Batista Júnior, University of Mogi das Cruzes, Brazil; Sergio Davinelli, University of Molise, Italy
Updates

Check for updates
Copyright
© 2019 Barclay, Burd, Tyler, Tillin and Mackenzie.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Richard W. Mackenzie richard.mackenzie@roehampton.ac.uk
This article was submitted to Clinical Nutrition, a section of the journal Frontiers in Nutrition
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.